chapter  12
8 Pages

Introduction

WithDenis M. Grant

From the preceding chapters, it is evident that there is a critical need to better understand the instances where pharmacogenomics will be of value for the pre-market development or the post-market prescribing of individualized medicines. In order to enable both the experimental assessment of the utility of pharmacogenomics and ultimately its reduction to routine clinical practice where appropriate, there is an ongoing need for improved assay methods for the analysis of single nucleotide polymorphisms (SNPs), the most abundant type of genetic variant in the human genome. The purpose of the present chapter is to provide a general discussion of strategic and experimental issues related to the choice of suitable genotyping methodologies for various research and clinical settings. The reader is referred to other chapters in this monograph that provide further technical details of many of the emerging SNP genotyping technologies that will be briefly summarized here.